Severe asthma biologic switching data hardens
Peer-reviewed real-world data on severe-asthma biologic switching is now sufficient to underpin payer policy and prescribing pathway design.
Real-world data on severe-asthma biologic switching has matured to the point that payer policy and clinical pathway design can rest on evidence. Roughly a quarter of patients switch within two years, mostly for inadequate response, with the destination of the switch increasingly phenotype-aligned.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.
Related
← Back to Signals
Published by PatientSpotlight, by PanaceaIntel.